NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
17 trialsNCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01355562 2020-04-30
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Phase 2 Withdrawn
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01702909 2018-02-08
Interleukin-2 in Metastatic Kidney Cancer
Western Regional Medical Center
Phase 2 Terminated
NCT00089778 2017-08-01
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00003126 2017-01-04
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Loyola University
Phase 3 Completed
NCT00440973 2016-03-17
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00328861 2012-11-05
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00091611 2012-10-26
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00031564 2012-09-27
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01176552 2010-08-24
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau
Phase 2 Completed